IP Library Granted Patent US 7,806,924
Granted Patent B2
US 7,806,924 · App. 10/780,596 · Granted Oct 5, 2010

Implantable structures for local vascular delivery of cladribine in combination with rapamycin for restenosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,806,924
App. No.
10/780,596
Granted
Oct 5, 2010
Kind
B2
Abstract

Medical devices, and in particular implantable structures, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization.

Claims (7)

1. A medical device comprising:

an implantable structure;

a basecoat matrix, including a combination of rapamycin and cladribine, in therapeutic dosages, incorporated in a first polymeric material comprising polyvinylidenefluoride-co-hexafluoropropylene with a weight ratio of 60 weight percent vinylidenefluoride to 40 weight percent hexafluoropropylene, the basecoat matrix being affixed to the surface of the implantable medical device, the concentration of cladribine being in the range from about fifty-six nano molar to about nine-hundred nano molar; and

a topcoat, including a second polymeric material comprising poly(n-butylmethacrylate), affixed to the basecoat matrix for controlling the elution rate of the combination of rapamycin and cladribine, wherein the second polymeric material is incompatible with the first polymeric material, thereby creating both a physical and chemical barrier to the elution of the rapamycin and cladribine.

2. The medical device according to claim 1 , wherein the implantable structure comprises a stent.

3. The medical device according to claim 1 , wherein the implantable structure comprises a stent-graft.

4. The medical device according to claim 1 , wherein the implantable structure comprises an anastomosis device.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2007
From: CORDIS CORPORATION
To: WYETH
Reel/Frame 020234/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2004
From: FALOTICO, ROBERT; PARRY, TOM JAY; ZHAO, JONATHON Z.
To: CORDIS CORPORATION
Reel/Frame 015456/0359 →